Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NOVAVAX INCNVAX · Entity 4632 | Director | June 18, 2026 | June 23, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NOVAVAX INC
Report date June 18, 2026 · Filed June 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.13 · Expires 2036-06-18 | Direct | 21,270 |
Reported balance
After 2026-06-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-18 · Grant · Acquired 21,270 · Balance 21,270 F1: One hundred percent (100%) of the shares subject to this option grant under the Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 14,180 |
Reported balance
After 2026-06-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-18 · Grant · Acquired 14,180 · Balance 14,180 F2: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. F3: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: One hundred percent (100%) of the shares subject to this option grant under the Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date.
F2: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock.
F3: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Icosavax, Inc.
Report date February 19, 2024 · Filed February 20, 2024
Section 16 reporting ended · disclosed 2024-02-20. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-02-19 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2024-02-19 · Other · Disposed 8,066 · Balance 0 F1: In connection with the terms of an Agreement and Plan of Merger, dated as of December 11, 2023 (the "Merger Agreement"), by and among the Issuer, AstraZeneca Finance and Holdings Inc. ("Parent"), and Isochrone Merger Sub Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's Common Stock at a purchase price per share of (i) $15.00 plus (ii) one non-tradable contingent value right ("CVR") per share representing the right to receive a contingent payment of up to $5.00 in cash upon achievement of specified milestones (collectively, the "Offer Price"). After completion of the tender offer, Purchaser merged with and into the Issuer (the "Merger"), effective as of February 19, 2024 (the "Effective Time"), with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-02-19 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2024-02-19 · Disposition to issuer · Disposed 2,833 · Balance 0 F2: Represents restricted stock units ("RSUs"). Pursuant to the Merger Agreement, immediately prior to the Effective Time, each RSU that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the contingent right to receive the Offer Price, subject to the terms of the Merger Agreement. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.25 | Direct | 0 |
Reported balance
After 2024-02-19 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-02-19 · Disposition to issuer · Disposed 9,643 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, this stock option was cancelled and converted into the right to receive, subject to the terms of the Merger Agreement, (a) an amount in cash equal to the product obtained by multiplying (1) the aggregate number of shares underlying such option immediately prior to the Effective Time by (2) an amount equal to (A) $15.00 less (B) the exercise price of such option, plus (b) one CVR for each share underlying such option immediately prior to the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.89 | Direct | 0 |
Reported balance
After 2024-02-19 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-02-19 · Disposition to issuer · Disposed 17,000 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, this stock option was cancelled and converted into the right to receive, subject to the terms of the Merger Agreement, (a) an amount in cash equal to the product obtained by multiplying (1) the aggregate number of shares underlying such option immediately prior to the Effective Time by (2) an amount equal to (A) $15.00 less (B) the exercise price of such option, plus (b) one CVR for each share underlying such option immediately prior to the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.50 | Direct | 0 |
Reported balance
After 2024-02-19 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-02-19 · Disposition to issuer · Disposed 25,500 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, this stock option was cancelled and converted for no consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: In connection with the terms of an Agreement and Plan of Merger, dated as of December 11, 2023 (the "Merger Agreement"), by and among the Issuer, AstraZeneca Finance and Holdings Inc. ("Parent"), and Isochrone Merger Sub Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's Common Stock at a purchase price per share of (i) $15.00 plus (ii) one non-tradable contingent value right ("CVR") per share representing the right to receive a contingent payment of up to $5.00 in cash upon achievement of specified milestones (collectively, the "Offer Price"). After completion of the tender offer, Purchaser merged with and into the Issuer (the "Merger"), effective as of February 19, 2024 (the "Effective Time"), with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent.
F2: Represents restricted stock units ("RSUs"). Pursuant to the Merger Agreement, immediately prior to the Effective Time, each RSU that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the contingent right to receive the Offer Price, subject to the terms of the Merger Agreement.
F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, this stock option was cancelled and converted into the right to receive, subject to the terms of the Merger Agreement, (a) an amount in cash equal to the product obtained by multiplying (1) the aggregate number of shares underlying such option immediately prior to the Effective Time by (2) an amount equal to (A) $15.00 less (B) the exercise price of such option, plus (b) one CVR for each share underlying such option immediately prior to the Effective Time.
F4: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, this stock option was cancelled and converted for no consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 18, 2026 Filed Jun 23, 2026 23:50 UTC | NOVAVAX INC NVAX · Entity 4632 | GrantRestricted Stock Units · Derivative | 14,180 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-076923 · tm2618639-2_4seq1.xml · derivative · entry 2 Shiver John W. · CIK 0001900372 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,180 Underlying: Common Stock · 14,180 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. F3 · derivative.exercise_date: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date. F3 · derivative.expiration_date: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 23:50 UTC | NOVAVAX INC NVAX · Entity 4632 | GrantStock Option (Right to Buy) · Derivative | 21,270 | $0.00 Strike: $9.13 | $0.00 |
DisclosureSEC source: 0001104659-26-076923 · tm2618639-2_4seq1.xml · derivative · entry 1 Shiver John W. · CIK 0001900372 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,270 Underlying: Common Stock · 21,270 shares Expires 2036-06-18 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to this option grant under the Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date. Read SEC document |
| March 10, 2026 Filed Mar 12, 2026 21:00 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionRestricted Stock Units · Derivative | 7,947 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-027143 · tm268599-1_4seq1.xml · derivative · entry 2 Shiver John W. · CIK 0001900372 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,893 Underlying: Common Stock · 7,947 shares Expires 2035-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The RSUs subject to this grant under the Restated 2015 Stock Incentive Plan will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of March 10, 2025, in each case subject to continued service on the Company's Board of Directors through such vesting date Read SEC document |
| March 10, 2026 Filed Mar 12, 2026 21:00 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 7,947 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-027143 · tm268599-1_4seq1.xml · nonDerivative · entry 1 Shiver John W. · CIK 0001900372 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,947 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 10, 2025 Filed Mar 13, 2025 00:04 UTC | NOVAVAX INC NVAX · Entity 4632 | GrantRestricted Stock Units · Derivative | 23,840 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-023077 · tm259047-2_4seq1.xml · derivative · entry 2 Shiver John W. · CIK 0001900372 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,840 Underlying: Common Stock · 23,840 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Company common stock. F3 · derivative.exercise_date: The RSUs subject to this grant under the Plan will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the Grant Date, in each case subject to continued service on the Company's Board of Directors through such vesting date. F3 · derivative.expiration_date: The RSUs subject to this grant under the Plan will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the Grant Date, in each case subject to continued service on the Company's Board of Directors through such vesting date. Read SEC document |
| March 10, 2025 Filed Mar 13, 2025 00:04 UTC | NOVAVAX INC NVAX · Entity 4632 | GrantStock Option (Right to buy) · Derivative | 35,770 | $0.00 Strike: $8.20 | $0.00 |
DisclosureSEC source: 0001104659-25-023077 · tm259047-2_4seq1.xml · derivative · entry 1 Shiver John W. · CIK 0001900372 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,770 Underlying: Common Stock · 35,770 shares Expires 2035-03-10 F1 · derivative.exercise_date: The shares subject to this option grant under the Novavax, Inc. (the "Company") Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan"), will vest with respect to one-third (1/3) of the shares on each of the first three (3) anniversaries of the March 10, 2025 grant date (the "Grant Date"), in each case subject to continued service on the Company's Board of Directors through such vesting date. Read SEC document |
| February 19, 2024 Filed Feb 20, 2024 19:41 UTC | Icosavax, Inc. ICVX · Entity 94107 | Disposition to issuerStock Option (Right to Buy) · Derivative | 25,500 | Not disclosed Strike: $22.50 | Not disclosed |
DisclosureSEC source: 0000950170-24-017407 · ownership.xml · derivative · entry 5 Shiver John W. · CIK 0001900372 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,500 shares Expires not disclosed F4 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, this stock option was cancelled and converted for no consideration. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, this stock option was cancelled and converted for no consideration. F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, this stock option was cancelled and converted for no consideration. Read SEC document |
| February 19, 2024 Filed Feb 20, 2024 19:41 UTC | Icosavax, Inc. ICVX · Entity 94107 | Disposition to issuerStock Option (Right to Buy) · Derivative | 17,000 | Not disclosed Strike: $9.89 | Not disclosed |
DisclosureSEC source: 0000950170-24-017407 · ownership.xml · derivative · entry 4 Shiver John W. · CIK 0001900372 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,000 shares Expires not disclosed F3 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, this stock option was cancelled and converted into the right to receive, subject to the terms of the Merger Agreement, (a) an amount in cash equal to the product obtained by multiplying (1) the aggregate number of shares underlying such option immediately prior to the Effective Time by (2) an amount equal to (A) $15.00 less (B) the exercise price of such option, plus (b) one CVR for each share underlying such option immediately prior to the Effective Time. F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, this stock option was cancelled and converted into the right to receive, subject to the terms of the Merger Agreement, (a) an amount in cash equal to the product obtained by multiplying (1) the aggregate number of shares underlying such option immediately prior to the Effective Time by (2) an amount equal to (A) $15.00 less (B) the exercise price of such option, plus (b) one CVR for each share underlying such option immediately prior to the Effective Time. F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, this stock option was cancelled and converted into the right to receive, subject to the terms of the Merger Agreement, (a) an amount in cash equal to the product obtained by multiplying (1) the aggregate number of shares underlying such option immediately prior to the Effective Time by (2) an amount equal to (A) $15.00 less (B) the exercise price of such option, plus (b) one CVR for each share underlying such option immediately prior to the Effective Time. Read SEC document |
| February 19, 2024 Filed Feb 20, 2024 19:41 UTC | Icosavax, Inc. ICVX · Entity 94107 | Disposition to issuerStock Option (Right to Buy) · Derivative | 9,643 | Not disclosed Strike: $6.25 | Not disclosed |
DisclosureSEC source: 0000950170-24-017407 · ownership.xml · derivative · entry 3 Shiver John W. · CIK 0001900372 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,643 shares Expires not disclosed F3 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, this stock option was cancelled and converted into the right to receive, subject to the terms of the Merger Agreement, (a) an amount in cash equal to the product obtained by multiplying (1) the aggregate number of shares underlying such option immediately prior to the Effective Time by (2) an amount equal to (A) $15.00 less (B) the exercise price of such option, plus (b) one CVR for each share underlying such option immediately prior to the Effective Time. F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, this stock option was cancelled and converted into the right to receive, subject to the terms of the Merger Agreement, (a) an amount in cash equal to the product obtained by multiplying (1) the aggregate number of shares underlying such option immediately prior to the Effective Time by (2) an amount equal to (A) $15.00 less (B) the exercise price of such option, plus (b) one CVR for each share underlying such option immediately prior to the Effective Time. F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, this stock option was cancelled and converted into the right to receive, subject to the terms of the Merger Agreement, (a) an amount in cash equal to the product obtained by multiplying (1) the aggregate number of shares underlying such option immediately prior to the Effective Time by (2) an amount equal to (A) $15.00 less (B) the exercise price of such option, plus (b) one CVR for each share underlying such option immediately prior to the Effective Time. Read SEC document |
| February 19, 2024 Filed Feb 20, 2024 19:41 UTC | Icosavax, Inc. ICVX · Entity 94107 | Disposition to issuerCommon Stock | 2,833 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-017407 · ownership.xml · nonDerivative · entry 2 Shiver John W. · CIK 0001900372 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F2 · shares: Represents restricted stock units ("RSUs"). Pursuant to the Merger Agreement, immediately prior to the Effective Time, each RSU that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the contingent right to receive the Offer Price, subject to the terms of the Merger Agreement. F2 · price: Represents restricted stock units ("RSUs"). Pursuant to the Merger Agreement, immediately prior to the Effective Time, each RSU that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the contingent right to receive the Offer Price, subject to the terms of the Merger Agreement. Read SEC document |
| February 19, 2024 Filed Feb 20, 2024 19:41 UTC | Icosavax, Inc. ICVX · Entity 94107 | OtherCommon Stock | 8,066 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-017407 · ownership.xml · nonDerivative · entry 1 Shiver John W. · CIK 0001900372 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: In connection with the terms of an Agreement and Plan of Merger, dated as of December 11, 2023 (the "Merger Agreement"), by and among the Issuer, AstraZeneca Finance and Holdings Inc. ("Parent"), and Isochrone Merger Sub Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's Common Stock at a purchase price per share of (i) $15.00 plus (ii) one non-tradable contingent value right ("CVR") per share representing the right to receive a contingent payment of up to $5.00 in cash upon achievement of specified milestones (collectively, the "Offer Price"). After completion of the tender offer, Purchaser merged with and into the Issuer (the "Merger"), effective as of February 19, 2024 (the "Effective Time"), with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent. Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 16:42 UTC | Icosavax, Inc. ICVX · Entity 94107 | GrantStock Option (Right to Buy) · Derivative | 17,000 | $0.00 Strike: $9.89 | $0.00 |
DisclosureSEC source: 0001209191-23-035454 · doc4.xml · derivative · entry 1 Shiver John W. · CIK 0001900372 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 17,000 shares Expires 2033-06-05 F1 · derivative.exercise_date: 1/12th of the total number of shares of common stock subject to the option vest monthly following June 6, 2023, the vesting commencement date, provided if the next occurring annual meeting of the Issuer's stockholders occurs prior to the full vesting of the option, any remaining options will vest on the date of such annual meeting, subject to the Reporting Person's continuous service on the board of directors of the Issuer through such vesting date. Read SEC document |
| June 10, 2022 Filed Jun 14, 2022 17:03 UTC | Icosavax, Inc. ICVX · Entity 94107 | GrantStock Option (Right to Buy) · Derivative | 9,643 | $0.00 Strike: $6.25 | $0.00 |
DisclosureSEC source: 0001209191-22-036742 · doc4.xml · derivative · entry 2 Shiver John W. · CIK 0001900372 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,643 Underlying: Common Stock · 9,643 shares Expires 2032-06-09 F2 · derivative.exercise_date: 1/12th of the total number of shares of common stock subject to the option vest monthly following June 10, 2022, the vesting commencement date, provided if the next occurring annual meeting of the Issuer's stockholders occurs prior to the full vesting of the option, any remaining options will vest on the date of such annual meeting, subject to the Reporting Person's continuous service on the board of directors of the Issuer through such vesting date. Read SEC document |
| June 10, 2022 Filed Jun 14, 2022 17:03 UTC | Icosavax, Inc. ICVX · Entity 94107 | GrantCommon Stock | 2,399 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-036742 · doc4.xml · nonDerivative · entry 1 Shiver John W. · CIK 0001900372 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,899 F1 · shares: Represents restricted stock units ("RSUs") which will vest on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on the board of directors of the Issuer through such vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer and the RSUs have no expiration date. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 19:34 UTC | Icosavax, Inc. ICVX · Entity 94107 | GrantStock Option (Right to Buy) · Derivative | 25,500 | $0.00 Strike: $22.50 | $0.00 |
DisclosureSEC source: 0001209191-22-002000 · doc4.xml · derivative · entry 2 Shiver John W. · CIK 0001900372 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,500 Underlying: Common Stock · 25,500 shares Expires 2032-01-02 F2 · derivative.exercise_date: 1/36th of the shares subject to the option vest monthly following January 3, 2022, the vesting commencement date. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 19:34 UTC | Icosavax, Inc. ICVX · Entity 94107 | GrantCommon Stock | 8,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-002000 · doc4.xml · nonDerivative · entry 1 Shiver John W. · CIK 0001900372 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,500 F1 · shares: Represents restricted stock units ("RSUs") granted on January 3, 2022. 1/3 of the total number of RSUs granted vest on each of the first three anniversaries of January 3, 2022, the vesting commencement date, subject to the reporting person's continued service on the applicable vesting date. Vesting of the RSUs shall accelerate upon a Change of Control (as defined in the Icosavax, Inc. 2021 Incentive Award Plan). Each RSU represents a contingent right to receive one share of common stock of the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.